The US pharmaceutical company Moderna announced that its Covid-19 vaccine has the potential to provide longer-term immunity. The company expects to be able to produce 20 million doses of the vaccine candidate in the United States by the end of this year. According to the National Institute of Allergy and Infectious Diseases, participants in a previous clinical vaccine study still had “high levels of neutralizing antibodies” three months after their first vaccination – or two months after their second vaccination. The study said the vaccine had “the potential to provide lasting” immunity. No serious adverse effects occurred after the two months. “These preliminary phase 1 data suggest that mRNA-1273, our vaccine candidate for Covid-19, can produce permanent neutralizing antibodies in all age groups, including older and older adults,” said Moderna.

Tags: suchen suche search tag anzeigen besucherzahl browser design domain inhalt jahr karpfen konto problem inhalt schalten modellbahn spielemax spiel tag webseite preise werbung

Reichsmarschall Göring hatte eine Märklin Modelleisenbahn >>> read more